Literature DB >> 8922560

Spasticity after stroke. Epidemiology and optimal treatment.

C F O'Brien1, L C Seeberger, D B Smith.   

Abstract

Spasticity following stroke reflects a spectrum of clinical problems including increased muscle tone, abnormal limb posture, excessive contraction of antagonist muscles and hyperactive cutaneous and tendon reflexes. The prevalence of stroke-related disability in stroke survivors is high, and spasticity may be a significant component of this. Management strategies include a multidisciplinary team approach utilising a variety of rehabilitation techniques. Although some interventions are well tolerated and fairly standardised, older adults may be particularly sensitive to drug treatment-related adverse effects. This article reviews some of the commonly employed interventions, such as oral medications, and some of the newer techniques, such as intrathecal baclofen infusion and botulinum toxin injections. The optimal management of spasticity following stroke in older adults requires careful goal setting and skilful combination of treatment modalities in order to produce the best outcome.

Entities:  

Mesh:

Year:  1996        PMID: 8922560     DOI: 10.2165/00002512-199609050-00004

Source DB:  PubMed          Journal:  Drugs Aging        ISSN: 1170-229X            Impact factor:   3.923


  33 in total

1.  Vigabatrin as spasmolytic drug.

Authors:  J Jaeken; P De Cock; P Casaer
Journal:  Lancet       Date:  1991 Dec 21-28       Impact factor: 79.321

2.  Intrathecal fentanyl alleviates spasticity in the presence of tolerance to intrathecal baclofen.

Authors:  C Chabal; L Jacobson; G Terman
Journal:  Anesthesiology       Date:  1992-02       Impact factor: 7.892

3.  Effect of treatment with botulinum toxin on spasticity.

Authors:  T K Das; D M Park
Journal:  Postgrad Med J       Date:  1989-04       Impact factor: 2.401

4.  Percutaneous phenol block of the musculocutaneous nerve to control elbow flexor spasticity.

Authors:  M A Keenan; E S Tomas; L Stone; L M Gerstén
Journal:  J Hand Surg Am       Date:  1990-03       Impact factor: 2.230

5.  Intrathecal baclofen for the management of severe spasticity.

Authors:  R H Acland
Journal:  N Z Med J       Date:  1993-04-14

6.  Intrathecal baclofen: does tolerance occur?

Authors:  M N Akman; P G Loubser; W H Donovan; M E O'Neill; C D Rossi
Journal:  Paraplegia       Date:  1993-08

7.  Intraspinal baclofen in the treatment of severe spasticity and spasms.

Authors:  J Sahuquillo; T Muxi; M Noguer; R Jodar; C Closa; E Rubio; L Garcia-Fernandez; J M Guitart
Journal:  Acta Neurochir (Wien)       Date:  1991       Impact factor: 2.216

8.  Effect of transdermal clonidine on spinal spasticity. A case series.

Authors:  S A Yablon; M L Sipski
Journal:  Am J Phys Med Rehabil       Date:  1993-06       Impact factor: 2.159

9.  The current neurologic burden of illness and injury in the United States.

Authors:  J F Kurtzke
Journal:  Neurology       Date:  1982-11       Impact factor: 9.910

10.  Baclofen and carbamazepine in supraspinal spasticity.

Authors:  H Fodstad; B C Ljunggren
Journal:  J R Soc Med       Date:  1991-12       Impact factor: 18.000

View more
  2 in total

1.  Phase-II Clinical Validation of a Powered Exoskeleton for the Treatment of Elbow Spasticity.

Authors:  Simona Crea; Marco Cempini; Stefano Mazzoleni; Maria Chiara Carrozza; Federico Posteraro; Nicola Vitiello
Journal:  Front Neurosci       Date:  2017-05-12       Impact factor: 4.677

2.  Cost-Utility Analysis of Incobotulinumtoxin-A Compared With Conventional Therapy in the Management of Post-Stroke Spasticity in Romania.

Authors:  Adina Turcu-Stiolica; Mihaela-Simona Subtirelu; Ana-Maria Bumbea
Journal:  Front Pharmacol       Date:  2020-01-16       Impact factor: 5.810

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.